BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10719809)

  • 1. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence is not a predictive factor for response to interferon-alpha therapy and development of hepatocellular carcinoma.
    Bae SH; Park YM; Yoo DG; Choi JY; Byun BH; Yang JM; Lee CD; Cha SB; Park DH; Kim BS
    J Korean Med Sci; 2000 Feb; 15(1):53-8. PubMed ID: 10719809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
    Enomoto N; Sakuma I; Asahina Y; Kurosaki M; Murakami T; Yamamoto C; Ogura Y; Izumi N; Marumo F; Sato C
    N Engl J Med; 1996 Jan; 334(2):77-81. PubMed ID: 8531962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
    Sarrazin C; Berg T; Lee JH; Teuber G; Dietrich CF; Roth WK; Zeuzem S
    J Hepatol; 1999 Jun; 30(6):1004-13. PubMed ID: 10406177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
    Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
    J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene.
    Horiike N; Michitaka K; Masumoto T; Okura I; Akbar SM; Onji M
    J Gastroenterol Hepatol; 1999 Apr; 14(4):345-51. PubMed ID: 10207784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma.
    Araujo OC; Barros JJ; do Ó KM; Nabuco LC; Luz CA; Perez RM; Niel C; Villela-Nogueira CA; Araujo NM
    J Med Virol; 2014 Feb; 86(2):217-23. PubMed ID: 24338810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
    Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
    J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
    Ogura S; Akuta N; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection.
    Aslan N; Bozdayi AM; Cetinkaya H; Sarioğlu M; Türkay C; Bozkaya H; Karayalçin S; Yurtaydin C; Uzunalimoğlu O
    Turk J Gastroenterol; 2004 Mar; 15(1):21-6. PubMed ID: 15264117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.